Market sell-off continues for 2nd day; Nifty ends below 24,200 level

Market sell-off continues for 2nd day; Nifty ends below 24,200 level


The domestic equity benchmarks ended with sharp losses today, extending sell-off for second consecutive trading session, as investor sentiment stayed cautious due to uncertainty over the reopening of the Strait of Hormuz and crude oil prices rising above $100 per barrel. Investors are also closely monitoring Q4 earnings for further cues. The Nifty settled below 24,200 level.

Pharma and media shares advanced while auto, PSU Bank and realty shares declined.

As per provisional closing data, the barometer index, the S&P BSE Sensex declined 852.49 points or 1.09% to 77,664. The Nifty 50 index slumped 205.05 points or 0.84% to 24,173.05. in the two consecutive trading session, the Sensex, and Nifty plunged 2.03% and 1.64%, respectively.

 

In the broader market, the BSE 150 MidCap Index shed 0.33% and the BSE 250 SmallCap Index fell 0.49%.

The market breadth was negative. On the BSE, 1,768 shares rose and 2,514 shares fell. A total of 174 shares were unchanged.

The NSE’s India VIX, a gauge of the market’s expectation of volatility over the near term, rose 1.58% to 18.59.

In the commodities market, Brent crude for June 2026 settlement jumped $1.49 or 1.46% to $103.40 a barrel.

Economy:

The HSBC Flash India PMI Composite Output Index was rose to 58.3 in April from the final reading of 57.0 in March. The latest reading signalled a sharp expansion in overall business activity, remaining well above its long-run average.

HSBC Flash India Services PMI Business Activity Index stood at 57.9 in April 2026 compared with 57.5 in March 2026.

Meanwhile, HSBC Flash India Manufacturing PMI Output Index climbed to 59.1 in April 2026 compared with 55.7 in March 2026. Overall manufacturing business conditions also strengthened, with the HSBC Flash India Manufacturing PMI rising to 55.9 in April from 53.9 in the previous month.

Buzzing Index:

The Nifty Auto index declined 2.35% to 25,828.10. The index declined 2.99% in the two straight trading sessions.

Ashok Leyland (down 4.66%), TVS Motor Company (down 4.03%), Samvardhana Motherson International (down 3.45%), Mahindra & Mahindra (down 3.24%), Hero MotoCorp (down 3.03%), Tata Motors Passenger Vehicles (down 2.74%), Sona BLW Precision Forgings (down 2.36%), Exide Industries (down 2.06%), Eicher Motors (down 1.9%) and Uno Minda (down 1.84%) declined.

Stocks in Spotlight:

Oracle Financial Services Software (OFSS) jumped 7.86% after the company reported a 30.72% increase in consolidated net profit to Rs 841.7 crore on a 20.33% rise in revenue from operations to Rs 2,065.2 crore in Q4 FY26 over Q4 FY25.

Sangam India declined 1.40%. The companys consolidated net profit zoomed 245.27% to Rs 32.87 crore in Q4 FY26 as against Rs 9.52 crore in Q4 FY25. Revenue from operations rose 20.37% year on year (YoY) to Rs 883.93 crore in Q4 FY26.

Trent tumbled 4.36%. The company reported a 29.95% jump in standalone net profit to Rs 454.75 crore on a 20.22% increase in revenue from operations to Rs 4,936.64 crore in Q4 FY26 over Q4 FY25.

Tips Music jumped 9.65% after the companys standalone net profit surged 92.91% to Rs 59.05 crore on 32.43% increase in revenue from operations to Rs 103.93 crore in Q4 FY26 over Q4 FY25.

Prizor Viztech was locked in 5% upper circuit at Rs 565 after the company reported 152.8% jump in net profit to Rs 14.84 crore on a 164.4% increase in revenues to Rs 105.93 crore in Q4 FY26 as compared with Q4 FY25.

Tata Communications jumped 4.85%. The company has reported 65.4% drop in consolidated net profit to Rs 263 crore despite a 9.4% rise in gross revenues to Rs 6,554 crore in Q4 FY26 as compared with Q4 FY25. The companys board has declared a dividend of Rs 17.50 per share for the financial year ended 31 March 2026.

Alembic Pharmaceuticals rose 0.76%. The company announced the incorporation of a new subsidiary in the Philippines, aimed at expanding its international presence.

Infosys declined 2.04%. The company has announced a strategic collaboration with OpenAI to help enterprises transform software development and modernization with OpenAIs frontier AI models and products like Codex.

KP Energy jumped 3.47% after the company received an inter-state electricity trading licence from the Central Electricity Regulatory Commission. The licence, classified under Category V, allows the company to undertake electricity trading across state boundaries and participate in national power markets.

Jio Financial Services rallied 4.28% after the company said that it has entered into a binding agreement with Allianz Group (Allianz) to form a 50:50 primary insurance joint venture (JV). The JV, covering the general insurance and health insurance segments, would serve the rapidly expanding Indian insurance sector. The partnership combines two financial services firms to offer protection products tailored to Indian individuals and businesses. Customers benefit from JFSLs digital reach and local market knowledge along with Allianzs insurance products and expertise.

Speciality Medicines hit an upper limit of 5% after the company announced a new export order from an international client. The company said it has entered into a commercial arrangement with a global distributor for pharmaceutical finished products worth about $2 million, or approximately Rs 18.8 crore.

Global Markets:

The Dow Jones index futures were down 276 points, indicating a negative opening in the US stocks today.

European market declined on Thursday as regional market sentiment remained subdued and oil prices edged higher.

The U.K. government borrowing fell by almost 20 billion to 132 billion in the financial year ending March 2026, according to new Office for National Statistics data.

Asian market ended lower on Thursday as investors noted ongoing tensions around the Strait of Hormuz despite U.S. President Donald Trumps indefinite extension to a ceasefire in the Iran war.

Trump extended a two-week U.S. ceasefire on Tuesday, saying it was warranted due to Tehrans seriously fractured government.

The ceasefire will remain in place until Iran submits a proposal or talks conclude, while the U.S. military continues its blockade of Iranian ports, Trump said.

However, the timeline remains uncertain. Iranian state media reported Wednesday that Tehrans negotiators would not attend talks with the U.S., calling them a “waste of time.

A lack of commitment from Iran reportedly prompted Vice President JD Vance to pause his trip to join peace talks.

Meanwhile, Irans navy also said that it had seized two container ships in the Strait of Hormuz.

On the data front, Japans manufacturing activity expanded at its fastest pace in four years in April, according to the S&P Global flash Purchasing Managers Index, as firms boosted output amid supply concerns linked to Middle East tensions.

The S&P Global flash Japan Manufacturing Purchasing Managers’ Index (PMI) rose to 54.9 in April, the highest since January 2022, from 51.6 in March. The 50-mark separates growth from contraction.

South Koreas economy grew more than expected in the first three months of the year, recording the fastest growth since the third quarter of 2020. The 1.7% growth in January to March from the previous quarter exceeded the widely reported estimate of 1.0% and reflects a rebound from the 0.2% contraction in the prior quarter.

Overnight on Wall Street, the S&P 500 and Nasdaq Composite finished at record levels on Wednesday after President Donald Trump extended the U.S. ceasefire with Iran, while upbeat earnings reports also lifted sentiment.

The broad market index added 1.05% to finish at 7,137.90, while the tech-heavy Nasdaq added 1.64% to settle at 24,657.57. Meanwhile, the Dow Jones Industrial Average advanced 340.65 points, or 0.69%, to end the day at 49,490.03.



Source link

Market sell-off continues for 2nd day; Nifty ends below 24,200 level

Bharat Coking Coal slides as Q4 PAT tanks 59% YoY to Rs 27 cr


Bharat Coking Coal tanked 5.35% to Rs 33.94 after its standalone net profit slipped 58.97% to Rs 27.28 crore in Q4 FY26 as against Rs 66.50 crore in Q4 FY25.

Revenue from operations fell 15.07% to Rs 3,282.95 crore in Q4 FY26 as against Rs 3,865.79 crore in Q4 FY25.

Profit befor tax stood at Rs 18.94 crore in Q4 FY26, down 70.50% as against Rs 64.22 crore in Q4 FY25.

Total expenses declined 6.53% to Rs 3,820.56 crore in Q4 FY26, compared to Rs 4,087.51 crore reported in Q4 FY25. The cost of materials consumed stood at Rs 153.75 crore (up 15.12% YoY), and employee benefit expenses were Rs 1,844.46 crore (up 4.64% YoY) during the period under review.

 

Bharat Coking Coal has approved a revision in the prices of washed coking coal, effective April 1, 2026, for the first quarter of FY27.

In line with the import parity pricing mechanism and its MoU with Steel Authority of India Limited, the board has fixed the base price of washed prime coking coal at Rs 13,403 per metric tonne (MT), while washed medium coking coal will be priced at Rs 10,937 per MT. Taxes, levies and other charges will be applicable over and above the base price.

The company has also approved a revision in evacuation charges for washery products with effect from April 1, 2026. The recovery rates have been set at Rs 731 and Rs 878 per MT for washed coal (PCC/MCC) at 65% yield, Rs 225 and Rs 270 per MT for washed power coal at 20% yield, and Rs 169 and Rs 202 per MT for rejects/slurry at 15% yield. These will be recovered through invoices in addition to existing evacuation charges.

Separately, the BCCL board has approved the waiver of performance incentive and price discounts offered to power consumers for lifting beyond 100% of the Annual Contracted Quantity (ACQ). The waiver applies to discounts of up to 10% across various slabs.

Bharat Coking Coal (BCCL) is engaged in the production of coking coal, non-coking coal, and washed coal.



Source link

Market sell-off continues for 2nd day; Nifty ends below 24,200 level

Sterling & Wilson Renewable Energy consolidated net profit rises 142.99% in the March 2026 quarter


Sales decline 22.77% to Rs 1945.61 crore

Net profit of Sterling & Wilson Renewable Energy rose 142.99% to Rs 134.57 crore in the quarter ended March 2026 as against Rs 55.38 crore during the previous quarter ended March 2025. Sales declined 22.77% to Rs 1945.61 crore in the quarter ended March 2026 as against Rs 2519.11 crore during the previous quarter ended March 2025.

For the full year,net loss reported to Rs 309.43 crore in the year ended March 2026 as against net profit of Rs 81.45 crore during the previous year ended March 2025. Sales rose 19.77% to Rs 7548.05 crore in the year ended March 2026 as against Rs 6301.86 crore during the previous year ended March 2025.

 ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.Sales1945.612519.11 -23 7548.056301.86 20 OPM %7.495.30 4.003.92 PBDT156.9989.85 75 351.98176.88 99 PBT154.1186.72 78 340.70162.54 110 NP134.5755.38 143 -309.4381.45 PL

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Apr 23 2026 | 2:31 PM IST



Source link

Market sell-off continues for 2nd day; Nifty ends below 24,200 level

Innovision receives toll collection and facilities maintenance contract of Rs 31.09 cr


Innovision has received a Letter of Award (LoA) /work order
engagement of user fee agency on the basis Competitive Bidding at Vembukudi fee plaza at Km 152.000 of Cholapuram- Thanjavur Section from Km 116.440 to Km 164.275 of NH-45C in the state of Tamil Nadu and upkeep /maintenance of adjacent toilet blocks including recouping the consumable items. The contract is valued at Rs 31.09 crore.
 

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Apr 23 2026 | 1:31 PM IST



Source link

Market sell-off continues for 2nd day; Nifty ends below 24,200 level

Websol Energy hits the roof as Kedia entry lifts sentiment


Websol Energy System hit the upper circuit of 10% at Rs 106.53 on Thursday, extending gains for a second consecutive session.

The stock has risen about 21% over the past two sessions after ace investor Vijay Kedia emerged in the companys latest shareholding data with a stake of around 1.02%, or 44.4 lakh shares, acquired during March.

Kedias name did not appear in the earlier shareholding pattern as of March 13. As per disclosure norms, shareholder names are reflected only when holdings exceed 1%, making it unclear whether the stake is a fresh entry or an increase in an existing position.

 

The stock has gained 39.18% over the past month and 42.31% over three months, though it remains down 30.22% on a one-year basis.

Websol Energy System is engaged in the business of manufacturing photovoltaic crystalline solar cells and related modules in India.

The company’s board will meet on 27 April 2026 to consider Q4 results and a final dividend. If declared, this would be the company’s first dividend announcement since September 2009.

The company reported a standalone net profit of Rs 64.98 crore in Q3 FY26, up 56.4% from Rs 41.56 crore in Q3 FY25. However, revenue from operations rose 77.2% year-on-year (YoY) to Rs 261.02 crore in Q3 FY26.

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Apr 23 2026 | 12:31 PM IST



Source link

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%



Nifty Pharma index movement

 


Shares of pharmaceutical companies were in demand with the Nifty Pharma index gaining 3 per cent to 23,164.10 in Thursday’s intra-day trade in an otherwise weak market.

 


Piramal Pharma and Dr Reddy’s Laboratories rallied 9 per cent and 8 per cent, respectively on the National Stock Exchange (NSE) in intra-day deals. 

 


Glenmark Pharmaceuticals, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Lifesciences, Laurus Labs, Ipca Labs, Divis Laboratories, Strides Pharma Science and Onesource Specialty Pharma were up in the range of 3 per cent to 6 per cent in intra-day trade.

 


At 10:53 AM on Thursday, the Nifty Pharma index was up 2.2 per cent, as compared to 0.71 per cent decline in the Nifty 50. The pharma index had hit a 52-week high of 23,540.90 on March 11, 2026.

 
 


Brokerages view on pharma stocks, sector

 


Shares of Piramal Pharma rallied 9 per cent to ₹168.50 on the NSE in intra-day trade. The stock was the top gainer among Nifty Pharma index.

 


JM Financial Institutional Securities maintains a ‘BUY’ rating on Piramal Pharma with a target price of ₹211.

 


Piramal Pharma has secured a new commercial contract for its overseas unit that, although small, adds to its expanding commercial portfolio and is likely to support profitability improvement at international subsidiaries. Botanix Pharmaceuticals has announced that it has on boarded Piramal Pharma as a secondary API supplier for Sofdra (sofpironium bromide), with manufacturing to be carried out at Piramal’s Riverview facility and scale-up expected fromFY28; the brokerage firm estimates peak revenue potential of $15mn–20mn from this opportunity.

 


Shares of Dr Reddy’s Labs soared 8 per cent to ₹1,313 in intra-day trade. The stock now trades close to Choice Institutional Equities’ target price of ₹1,315. It had hit a 52-week high of ₹1,377.95 June 12, 2025.

 


Dr Reddy’s is the first to introduce a Drugs Controller General of India (DCGI)-approved version in India under the brand name Obeda, establishing an early-mover advantage in the domestic GLP-1 market.

 


The company’s premium pricing at ₹4,200 per month versus peers at ₹1,300 reflects its dosage form, with a prefilled disposable pen format as compared to vial-based alternatives, which could support greater physician preference and patient stickiness. The brokerage firm in the company update note said that they view this launch as positioning the company strategically within the emerging GLP-1 opportunity, with a differentiated focus on quality, delivery format and brand trust rather than price-led competition.

 


“Overall, in the medium term, we expect a shift towards a more consolidated, quality-led market, with Dr Reddy’s well-placed to benefit given its early entry and manufacturing strengths,” the brokerage firm said.

 


Meanwhile, Indian Pharma Market (IPM) posted monthly growth of 10.7 per cent in March 2026, moderating from 12.5 per cent in February 2026 partly due to a firmer base of 9.5 per cent in March 2026, yet sustaining four consecutive months of double-digit expansion.

 


Chronic therapies sustained their outperformance, with share continuing its steady ascent above 40 per cent, while acute growth held up reasonably, aided by ongoing base normalization. March data reinforces the chronic anchor in IPM, with cardiac delivering 14.9 per cent monthly growth and retaining its position as the largest therapy at 13.9 per cent share, according to analysts at Equirus Securities.

 


March 2026 growth was characterised by notable individual company divergence. Dr. Reddy’s delivered a standout 18.2 per cent monthly print while Lupin (14.6 per cent) extended its strong run, with volume driven gains. Sun Pharma and Torrent maintained above-IPM performance, reflecting the sustained depth of their chronic franchises. Mankind staged a meaningful recovery, the brokerage firm said in sector report.

 


Meanwhile, analysts at BNP Paribas India expect India formulations revenue to clock double-digit growth during the quarter for its entire coverage (excluding Zydus Life). However, the brokerage firm expects US revenue to remain under pressure due to loss of revenue from key products like Revlimid and Lanreotide, which would ultimately trickle down to EBITDA margin.  ======================================  Disclaimer: View and outlook shared on the stock belong to the respective brokerages and are not endorsed by Business Standard. Readers discretion is advised. 

 



Source link

YouTube
Instagram
WhatsApp